Revenue grew 16% year-over-year in Q2 2026, with EBIT more than doubling and gross margin rising to 70%. Delays in prescription processes impacted timing but not demand, and the company completed a key acquisition in Italy while maintaining strong cash flow and reaffirming long-term growth and marg…
Revenue grew 16% year-over-year in Q2 2026, with EBIT more than doubling and gross margin rising to 70%. Delays in prescription processes impacted timing but not demand, and the company completed a key acquisition in Italy while maintaining strong cash flow and reaffirming long-term growth and margin targets.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
